CSL signs Alentis deal for claudin1 drug, shares trade near A$177
AI مارکیٹ کا خلاصہ
CSL announced an exclusive global partnership with Alentis to develop and commercialise lixudebart (claudin-1), paying US$355m upfront and funding development, with profit-sharing 55/45. The asset is in Phase 2 for a rare autoimmune kidney disease, so near-term financial impact is uncertain, but it signals continued pipeline investment and strengthens CSL's nephrology strategy alongside margin-recovery efforts in plasma-derived therapies.
اثر کی سطح
● لو
متاثرہ اثاثے
NCCOGOLD2USD/USDT+0.81%
AI تجزیاتی سمجھ · NCCOGOLD2USD/USDTAI تجزیاتی سمجھ
● Neutral
ابھی ٹریڈ کریں
⚠️ AI سے تیار کردہ تجزیاتی سمجھ خبروں کے مواد پر مبنی ہے اور صرف معلوماتی مقاصد کے لیے فراہم کی گئی ہے۔ یہ سرمایہ کاری کا مشورہ نہیں ہے اور نہ ہی BingX کے خیالات کی نمائندگی کرتی ہے۔ سرمایہ کاری میں رسک شامل ہے۔ براہ کرم ذمہ داری سے ٹریڈ کریں۔
CSL Limited said it has struck a drug-development partnership with Alentis focused on an investigational claudin1-targeting therapy now in a Phase 2 trial for a rare autoimmune kidney disease. CSL will pay US$355 million upfront and fund the planned development program, while the companies would split global profits 55% to CSL and 45% to Alentis if the treatment reaches the market. CSL shares were trading around A$177 on Tuesday, implying a price-to-earnings multiple of just under 20 times FY27 consensus earnings per share of A$8.99, falling to about 17.5 times based on FY29 EPS of A$10.08.
